Cargando…

Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism

CONTEXT: Inhibitors of the protease neprilysin (NEP) are used for treating heart failure, but are also linked to improvements in metabolism. NEP may cleave proglucagon-derived peptides, including the glucose and amino acid (AA)-regulating hormone glucagon. Studies investigating NEP inhibition on glu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kjeldsen, Sasha A S, Hansen, Lasse H, Esser, Nathalie, Mongovin, Steve, Winther-Sørensen, Marie, Galsgaard, Katrine D, Hunt, Jenna E, Kissow, Hannelouise, Ceutz, Frederik R, Terzic, Dijana, Mark, Peter D, Plomgaard, Peter, Goetze, Jens P, Goossens, Gijs H, Blaak, Ellen E, Deacon, Carolyn F, Rosenkilde, Mette M, Zraika, Sakeneh, Holst, Jens J, Wewer Albrechtsen, Nicolai J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317634/ https://www.ncbi.nlm.nih.gov/pubmed/34337276 http://dx.doi.org/10.1210/jendso/bvab084

Ejemplares similares

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2022)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice
por: Galsgaard, Katrine D., et al.
Publicado: (2022)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R–dependent manner
por: Jepsen, Sara L., et al.
Publicado: (2021)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

SAT037 Glucagon-like Peptide-1 Receptor Knockout Mice Do Not Compensate For The Lack Of Incretin Action By Increasing Glucose-dependent Insulinotropic Polypeptide Secretion
por: Douglas Galsgaard, Katrine, et al.
Publicado: (2023)

Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx
por: Zraika, Sakeneh, et al.
Publicado: (2013)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

The Liver–α-Cell Axis in Health and in Disease
por: Richter, Michael M., et al.
Publicado: (2022)

Effect of Pancreatic Hormones on pro-Atrial Natriuretic Peptide in Humans
por: Zois, Nora E., et al.
Publicado: (2017)

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
por: Kjeldsen, Sasha A.S., et al.
Publicado: (2023)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Neprilysin Is Required for Angiotensin-(1–7)’s Ability to Enhance Insulin Secretion via Its Proteolytic Activity to Generate Angiotensin-(1–2)
por: Brar, Gurkirat S., et al.
Publicado: (2017)

Intestinal Adaptation upon Chemotherapy-Induced Intestinal Injury in Mice Depends on GLP-2 Receptor Activation
por: Billeschou, Anna, et al.
Publicado: (2021)

Dietary Fiber Is Essential to Maintain Intestinal Size, L-Cell Secretion, and Intestinal Integrity in Mice
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Methods and Guidelines for Measurement of Glucagon in Plasma
por: Holst, Jens J., et al.
Publicado: (2019)

Intestinal Growth in Glucagon Receptor Knockout Mice Is Not Associated With the Formation of AOM/DSS-Induced Tumors
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy
por: Sampson Kjeldsen, Sasha Alexandra, et al.
Publicado: (2023)

Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice
por: Hytting-Andreasen, Rasmus, et al.
Publicado: (2018)

Does diabetes risk after SARS-CoV-2 infection depend on the viral variant?
por: Rangu, Rohita, et al.
Publicado: (2022)

Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas
por: Kuhre, Rune E., et al.
Publicado: (2018)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease
por: Werge, Mikkel Parsberg, et al.
Publicado: (2021)

Molecular and in vivo phenotyping of missense variants of the human glucagon receptor
por: van der Velden, Wijnand J.C., et al.
Publicado: (2021)

A Mouse Model of Beta-Cell Dysfunction as Seen in Human Type 2 Diabetes
por: Parilla, Jacqueline H., et al.
Publicado: (2018)

Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease
por: Balk-Møller, Emilie, et al.
Publicado: (2019)

Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells
por: Elmelund, Emilie, et al.
Publicado: (2022)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
por: Ronn, Jonas, et al.
Publicado: (2017)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

On the relationship between glucose absorption and glucose‐stimulated secretion of GLP‐1, neurotensin, and PYY from different intestinal segments in the rat
por: Kuhre, Rune E., et al.
Publicado: (2017)

Health care professionals from developing countries report educational benefits after an online diabetes course
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell Transplantation
por: Ebbesen, Maria, et al.
Publicado: (2021)

Normalization of elevated cardiac, kidney, and hemolysis plasma markers within 48 h in Mexican Tarahumara runners following a 78 km race at moderate altitude
por: Christensen, Dirk L, et al.
Publicado: (2014)

Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation
por: Larger, Etienne, et al.
Publicado: (2016)

Acute administration of interleukin‐6 does not increase secretion of glucagon‐like peptide‐1 in mice
por: Christiansen, Charlotte B., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ptgj10jvl96f0l68b3gvu7ld1s